Parkinson’s

Neurons
#Harvard Medical School #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Potential disease-modifying therapy for Parkinson’s disease

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. The peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD) mouse model’ was the result of collaborative… Read More

#Editor's Choice #News

Neurons in Parkinson's disease
#Cerevance #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase II trial

First-in-class non-dopamine Parkinson’s therapy enters Phase II

Cerevance has dosed the first patient in its ASCEND Phase II study to assess the efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease. In February 2023 the company expanded its Series B funding round, raising a total of $116 million. … Read More

#News

Parkinson's disease
#Gain Therapeutics #Genetics / genomics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Allosteric therapy targets common genetic cause of Parkinson’s

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. Preclinical data demonstrated that GT-02287 can restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which becomes misfolded and dysfunctional due to a… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Bayer #BlueRock Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Stem cells

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More

#News #Trending News

Autophagy
#ALS #Autophagy #Healthspan #Neurodegenerative disorders #Parkinson's #Turning Science into Business

Turning Science into Business: Inducing autophagy to treat disease

DDW’s Diana Spencer speaks to Peter Hamley, Chief Scientific Officer of Samsara Therapeutics, to understand the role autophagy plays in neurodegenerative diseases and how boosting this process could increase healthspan. DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. What is… Read More

#Exclusive Content

Neurons in a brain with Alzheimer's disease
#Alzheimer's #epilepsy #Neuroinflammation #Parkinson's #Phase I trial #Ventus Therapeutics

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Based on the safety margins demonstrated in IND-enabling studies, the Phase I trial is designed to fully explore VENT-02’s pharmacodynamics, safety, and… Read More

#News

Human neurone
#Artificial intelligence (AI) #Francis Crick Institute #Neurodegenerative disorders #Neurology #Parkinson's #Personalised medicine

AI Parkinson’s discovery paves way for personalised treatments

A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology… Read More

#News #Trending News

Esther Sammler
#Biogen #Clinical trial #Denali Therapeutics #Neurodegenerative disorders #Parkinson's #University of Dundee

New trial will investigate LRRK2 inhibitors for Parkinson’s

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of… Read More

#Editor's Choice #News

World Parkinson's Day
#Drug development #Drug discovery #Neurodegenerative disorders #Parkinson's

World Parkinson’s Day: New drug research

It is World Parkinson’s Day (11 April), raising awareness of the fastest growing neurological condition in the world. There is currently no cure, and although there are therapeutics to manage the symptoms, these usually bring side-effects, and so there is still need for new therapeutic options. Here, we take a… Read More

#Exclusive Content #Trending News

Brain Awareness Week
#Brain #Brain Awareness Week #Brain disease #Dementia #Drug discovery #Parkinson's #Stroke

Brain Awareness Week: the wonders of brain science

DDW’s Diana Spencer reviews some of the advances in drug discovery for diseases of the brain in the last month. Brain Awareness Week is an annual global campaign that takes place from March 13-19, aimed at raising awareness and support for brain science and issues related to the brain and… Read More

#Exclusive Content

Neurons in Parkinson's disease
#Genetics / genomics #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's #University of Queensland

Focus on autophagy could lead to more effective Parkinson’s drugs

Researchers have identified that a gene associated with an increased risk of Parkinson’s Disease also contributes to a build-up of cell debris in the brain. Dr Adekunle Bademosi from The Queensland Brain Institute said the discovery could change the focus of Parkinson’s Disease treatment. Without the… Read More

#News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News

Lissodendoryx florida
#Molecular Biology #Organic chemistry #Parkinson's #Synthetic chemistry

Synthesised sea sponge molecule could fight Parkinson’s

Organic chemists at the University of California, Los Angeles (UCLA) have created the first synthetic version of a molecule recently discovered in a sea sponge that may have therapeutic benefits for Parkinson’s disease and similar disorders.  The molecule, known as lissodendoric acid A, appears to… Read More

#News

Brain inflammation
#Alzheimer's #Brain disease #Neurodegenerative disorders #Neuroinflammation #Neurology #Parkinson's

Covid-19 triggers inflammation in the brain

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ… Read More

#Covid-19 #News